Free US stock insider buying and selling tracking with regulatory filing analysis for inside information on company health. We monitor corporate insider transactions because company officers often have the best understanding of their business prospects.
Ahead of its upcoming fiscal 2026 first-quarter earnings release, Regeneron Pharmaceuticals (NASDAQ: REGN) received a bullish rating update from TD Cowen, which lifted its 12-month price target 9.1% to $960 from $880 while reaffirming a Buy rating. The revision follows the U.S. FDA’s accelerated app
Regeneron Pharmaceuticals (REGN) - TD Cowen Ups Price Target Ahead of Fiscal Q1 Results, Supported by FDA Gene Therapy Approval - Revenue Beat
REGN - Stock Analysis
3993 Comments
1214 Likes
1
Jonnell
Active Contributor
2 hours ago
Real-time US stock currency and international exposure analysis for understanding global business impacts on company earnings and valuations. We help you understand how exchange rates and international operations affect your portfolio companies and their financial performance. We provide currency exposure analysis, international revenue breakdown, and forex impact modeling for comprehensive coverage. Understand global impacts with our comprehensive international analysis and exposure tools for global portfolio management.
👍 140
Reply
2
Quinshawn
Consistent User
5 hours ago
Comprehensive US stock research database with expert analysis, financial metrics, and comparison tools for smart stock selection. We aggregate data from multiple sources to provide you with a complete picture of any investment opportunity.
👍 242
Reply
3
Darik
Registered User
1 day ago
Too late for me… sigh.
👍 205
Reply
4
Demarlo
Community Member
1 day ago
Anyone else just trying to keep up?
👍 141
Reply
5
Zaryia
Legendary User
2 days ago
The passion here is contagious.
👍 267
Reply
© 2026 Market Analysis. All data is for informational purposes only.